Wirkstoffe & Arzneimittelsicherheit

Nebenwirkungen · Mycamine

Mycamine 50 mg powder for concentrate for solution for infusion Mycamine 100 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 6–7

HOS-117355 · Präparat HOS-094585

6 System Organ Common Uncommon Rare Not known Class ≥ 1/100 to < 1/10 ≥ 1/1,000 to < 1/100 ≥ 1/10,000 to (frequency < 1/1,000 cannot be estimated from available data) Endocrine hyperhidrosis disorders Metabolism and hypokalaemia, hyponatraemia, nutritional hypomagnesaemia, hyperkalaemia, disorders hypocalcaemia hypophosphataemia, anorexia Psychiatric insomnia, anxiety, disorders confusion Nervous system headache somnolence, tremor, disorders dizziness, dysgeusia Cardiac disorders tachycardia, palpitations, bradycardia Vascular disorders phlebitis hypotension, shock hypertension, flushing Respiratory, dyspnoea thoracic and mediastinal disorders Gastrointestinal nausea, vomiting, dyspepsia, disorders diarrhoea, abdominal constipation pain Hepatobiliary blood alkaline hepatic failure (see hepatocellular disorders phosphatase section 4.4), gamma- damage increased, aspartate glutamyltransferase including fatal aminotransferase increased, jaundice, cases (see increased, alanine cholestasis, section 4.4) aminotransferase hepatomegaly, increased, blood hepatitis bilirubin increased (including hyperbilirubinaemia), liver function test abnormal Skin and rash urticaria, pruritus, toxic skin subcutaneous erythema eruption, tissue disorders erythema multiforme, Stevens- Johnson syndrome, toxic epidermal necrolysis (see section 4.4) Renal and urinary blood creatinine renal disorders increased, blood urea impairment increased, renal (see section failure aggravated 4.4), acute renal failure

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.